Recent Posts
- Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future
- Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
- Q&A with Scancell CMO Nermeen Varawalla
- Director Dealing
- AACR (American Association for Cancer Research) Annual Meeting, April 2025, Chicago, Illinois
Recent Comments
No comments to show.